DexCom, Inc. (NASDAQ:DXCM) will announce its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) EPS. On average, analysts expect DexCom to post $-0.80 EPS for the current fiscal year and $-0.40 EPS for the next fiscal year.

Shares of DexCom, Inc. (DXCM) opened at 44.78 on Monday. The stock’s market cap is $3.88 billion. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80. The company has a 50-day moving average of $59.40 and a 200 day moving average of $69.45.

TRADEMARK VIOLATION WARNING: “DexCom, Inc. (DXCM) to Release Quarterly Earnings on Monday” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/23/dexcom-inc-dxcm-to-release-quarterly-earnings-on-monday.html.

DXCM has been the subject of a number of research analyst reports. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Piper Jaffray Companies restated a “buy” rating and issued a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. BMO Capital Markets restated a “buy” rating and issued a $105.00 price target on shares of DexCom in a research report on Thursday, July 13th. Cowen and Company restated a “buy” rating and issued a $90.00 price target on shares of DexCom in a research report on Friday, July 14th. Finally, Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $72.19.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total value of $416,040.00. The disclosure for this sale can be found here. Insiders sold a total of 21,573 shares of company stock valued at $1,524,286 in the last 90 days. 1.70% of the stock is owned by company insiders.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.